Endolymphatic isotope and BCG in the management of malignant melanoma.
Endolymphatic isotope therapy had such promising early clinical results that the M.R.C. (Medical Research Council) U.K. set up a clinical trial in 1966. This was to compare the effect of endolymphatic isotope therapy with the results of standard methods in the treatment of lower limb malignant melanoma. The interim report had three groups for analysis: Standard Methods (S); Endolymphatic Satisfactory (ES); and Endolymphatic Unsatisfactory (EU). This third group was a subdivision, as a significant number of patients did not have the correct endolymphatic treatment. The five-year survival figures expressed as actuarial percentages were ES=78.8%; S=82.3%; and EU=57.3%. Lymph node recurrence showed a significant difference: ES=2.3%; EU=12%; and S=19%. The conclusions were that endolymphatic isotope therapy was justified in specialized centres where good results could be obtained. Further animal experiments using the VX2 tumour in rabbits indicated that BCG given intracutaneously or intravenously had no therapeutic effect, whereas when applied by intralymphatic injection BCG was successful in treating lymph node metastases. Nineteen patients with poor-prognosis malignant melanoma have received endolymphatic BCG. The clinical results are recorded in this paper and are sufficiently encouraging to warrant its continued use.
D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007272:Injections, Intralymphatic; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D008875:Middle Aged; D009374:Neoplasms, Experimental / Q000628:therapy; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D011817:Rabbits; D012878:Skin Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*
D001500:BCG Vaccine; D007457:Iodine Radioisotopes; D010761:Phosphorus Radioisotopes